Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F18%3A00492495" target="_blank" >RIV/61388963:_____/18:00492495 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/17:73584400 RIV/61989592:15310/17:73584400 RIV/00216208:11310/18:10370243

Result on the web

<a href="http://dx.doi.org/10.1016/j.aca.2017.10.008" target="_blank" >http://dx.doi.org/10.1016/j.aca.2017.10.008</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.aca.2017.10.008" target="_blank" >10.1016/j.aca.2017.10.008</a>

Result language

angličtina

Original language name

Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy

Original language description

Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a promising role for direct imaging. GCPII is considerably over-expressed on cancerous prostatic epithelial cells, its analysis typically follows radiological or spectrophotometric principles. Its role as a biomarker present in blood has been recently investigated and potential correlation between a concentration of GCPII and prostate cancer has been proposed. The wider inclusion of GCPII detection in clinical praxis limits mainly the time and cost per analysis. Here, we present a novel analytical nanosensor applicable to quantification of GCPII in human whole blood consisted of Fe3O4@Ag magnetic nanocomposite surface-functionalized by an artificial antibody (low-molecular-weight GCPII synthetic inhibitor). The nanocomposite allows a simple magnetic isolation of GCPII using external magnetic force and its consecutive determination by magnetically assisted surface enhanced Raman spectroscopy (MA-SERS) with a limit of detection 6 pmol. L-1. This method enables a rapid determination of picomolar concentrations of GCPII in whole human blood of healthy individuals using a standard addition method without a complicated sample pre-treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10608 - Biochemistry and molecular biology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Analytica Chimica Acta

ISSN

0003-2670

e-ISSN

—

Volume of the periodical

997

Issue of the periodical within the volume

Jan 2

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

8

Pages from-to

44-51

UT code for WoS article

000415334500006

EID of the result in the Scopus database

2-s2.0-85033995055